ArticleJournal of clinical hypertension (Greenwich, Conn.)2010
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Renin inhibitors versus angiotensin receptor blockers for primary hypertension.The Cochrane database of systematic reviews · 2025Pooled it
- Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2020Pooled it
- The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.Journal of human hypertension · 2019Pooled it
- Blood pressure lowering efficacy of renin inhibitors for primary hypertension.The Cochrane database of systematic reviews · 2017Pooled it
- The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2012Pooled it
- Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.Clinical drug investigation · 2011Trial
- An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.Current cardiology reviews · 2022Review
- Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine.Clinical reviews in allergy & immunology · 2021Review
- Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.Bioorganic & medicinal chemistry · 2020Review
- Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports.PloS one · 2020Article
- Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics.Frontiers in genetics · 2019Review
- Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.Oncotarget · 2017Review
- Drug-induced hyperkalemia.Drug safety · 2014Review
- Renin inhibitors in diabetes and hypertension: an update.EXCLI journal · 2014Review
- Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.Therapeutic advances in chronic disease · 2013Article
- Delayed presentation of ACE inhibitor-induced angio-oedema.BMJ case reports · 2013Article
- Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science.Hypertension research : official journal of the Japanese Society of Hypertension · 2013Review
- Direct renin inhibition--a promising strategy for renal protection?Medical science monitor : international medical journal of experimental and clinical research · 2013Review
- Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.Journal of clinical hypertension (Greenwich, Conn.) · 2011Article
- A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.Vascular health and risk management · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
While the safety of renin-angiotensin system (RAS)-blocking drugs such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers is well known, less is known about the new direct renin inhibitor aliskiren. The authors pooled data from 12 randomized controlled trials of aliskiren in patients with hypertension and analyzed the incidence and types of adverse events (AEs) and laboratory abnormalities. Studies were characterized as short-term (≤2 months) placebo-controlled or long-term (>2 months) active-controlled. Relative risks for AEs of particular interest for RAS blockers were calculated. In short-term studies, AEs occurred in similar proportions of aliskiren 150 mg and 300 mg (33.6% and 31.6%, respectively) and placebo treatment groups (36.8%). In long-term studies, a lower proportion of patients treated with aliskiren 150 mg and 300 mg had AEs (33.7% and 43.2%, respectively) than those treated with ACE inhibitors (60.1%), angiotensin receptor blockers (53.9%), and thiazide diuretics (48.9%). Events of special interest, including angioedema, hyperkalemia, and diarrhea occurred in similar proportions of patients taking aliskiren, placebo, and comparator agents. In studies of up to 36 weeks, patients treated with aliskiren were significantly less likely to develop cough than those treated with ACE inhibitors. At the registered doses of 150 mg and 300 mg daily, aliskiren has safety and tolerability profiles similar to placebo, other RAS blockers, and diuretics. Cough rates are lower with aliskiren compared with ACE inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.